CN108125964A - δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury - Google Patents
δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury Download PDFInfo
- Publication number
- CN108125964A CN108125964A CN201810096090.7A CN201810096090A CN108125964A CN 108125964 A CN108125964 A CN 108125964A CN 201810096090 A CN201810096090 A CN 201810096090A CN 108125964 A CN108125964 A CN 108125964A
- Authority
- CN
- China
- Prior art keywords
- extract
- dichloromethane
- stringy stonecrop
- amyrenone
- hepatic injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Application the invention discloses δ amyrenones (δ amyrone) or with δ amyrone extracts as main component in the drug for preparing protection hepatic injury; using δ amyrone extracts as main component as stringy stonecrop dichloromethane extract, extracting method is as follows：Stringy stonecrop drying herb is cleaned, it is extracted with the ethyl alcohol that volume fraction is 95%, ethyl alcohol adds in volume and is equivalent to 6 times of medicinal material weight in extraction process, medicinal extract is condensed into, medicinal extract passes through silicagel column, is first eluted to petroleum ether colourless, again with dichloromethane eluent to colourless, dichloromethane eluant is collected, recycles dichloromethane organic solution, the medicinal extract after concentration is freeze-dried up to stringy stonecrop dichloromethane extract；Present invention firstly discovers that stringy stonecrop dichloromethane extract has liver-protecting activity, stringy stonecrop is further developed and used and is of great significance.
Description
Technical field
The present invention relates to a kind of Chinese medical extract, specifically δ-amyrenone (δ-amyrone) or based on δ-amyrone
Application of the extract of ingredient in the drug for preparing protection hepatic injury is wanted, is with δ-amyrone extracts as main component
It is prepared by raw material of sengreen.
Background technology
China is the higher country of hepatopathy incidence, and present various environmental factors and bad life habits cause various livers
The incidence of disease such as hepatitis, hepatic sclerosis, fatty liver, liver cancer etc. constantly rises, and how effective prevention and treatment hepatopathy has become
For one of medicine sector's facing challenges.Many liver diseases have a kind of common pathological state, are exactly hepatic injury.Chemical poison
The various adverse factors such as object, hepatotoxic medication, viral infection, alcohol are likely to the exception for causing liver function, in turn result in liver
Damage.It is now recognized that mainly by caused by the mechanism such as oxidative stress and inflammatory reaction.Lasting or serious hepatic injury is often
It is to lead to hepatic sclerosis, the liver failure even important initiating agent of liver cancer.Therefore, prevention hepatic injury is clinical treatment hepatopathy
One of key link is the basis for inhibiting various hepatopathy occurrence and development.At present, the Western medicine of this kind of disease of clinical treatment mainly divides
Into two classes：When antiviral agent, such as Lamivudine, interferon；Second is that protecting liver, lowering enzymes medicine, such as bicyclic alcohols, bifendate.So
And these Western medicine action target spots relatively it is single clearly, and focus on correct target organ pathological change, therefore the cause of disease clearly, hair
It is dominant in the clear disease treatment of Anttdisease Mechanism, but hepatic injury has multifactor, too many levels pathogenesis, single target spot, list
The Western medicine Long term therapy effect of link effect is not highly desirable, and rebound rate is high after easily generating drug withdrawal, and long-term use is also easy to produce
The problems such as drug resistance, so as to which clinical practice receives restriction.And Chinese medicine effect characteristic be exactly effective ingredient in Chinese be typically by
Multiple active ingredient compositions, multiple ingredients act on simultaneously and the relevant multiple target spots of disease, and therapeutic effect is played by multipath,
This meets the characteristics of hepatic injury cause of disease diversity and mechanism complexity very much, has certain advantage in terms of hepatic injury is treated.In
Medicine has long history in terms of liver protecting.Early have in ancient records in ancient times the disease symptoms such as liver depression, jaundice, hypochondriac pain with
Hepatic injury similar record and discussion.With the development of modern medicine, to the understanding of traditional Chinese medicine prevention hepatic injury via drop
The shallow-layers such as low transaminase face is gradually deep into cellular and molecular level.Common liver protecting Chinese medicine has simple, also has compound medicine,
It links is mainly immunized etc. by protecting liver, lowering enzymes, liver protection plays prophylactic treatment and act on.In recent years, have in some liver protections of document report
When long-term or high dose is applied, there is also toxic reactions, clinical application to be restricted for medicine.
Stringy stonecrop is the drying herb of Crassulaceae sengreen stringy stonecrop Sedum sarmentosum Bunge, is《In
State's pharmacopeia》One of conventional Chinese medicine recorded, and the young tender part of plant can have higher safety, poison for vegetable consumption
The smaller feature of side effect.It is reported that the extract of the larger solvent of stringy stonecrop polarity, such as water extract, alcohol extracting thing have
Liver-protecting activity, chemical composition are mainly flavones, cyanogen glycosides, sesquiterpenoids.But related stringy stonecrop low polar solvent, such as dichloromethane
Whether alkane extract has not been reported with liver-protecting activity.
Invention content
One of the objects of the present invention is to provide δ-amyrone (δ-amyrenone) or using δ-amyrone as main component
Extract prepare protection hepatic injury drug in application；The second object of the present invention is to provide a kind of protection hepatic injury
Stringy stonecrop dichloromethane extract preparation method；The third object of the present invention is to provide the preparation method of δ-amyrone.
For achieving the above object, the present invention provides following technical solution：
1st, δ-amyrone or with δ-amyrone extracts as main component prepare protection hepatic injury drug in
Using.
Preferably, the mass fraction with δ-amyrone extract δ-amyrone as main component is more than 50%.
It is it is furthermore preferred that described using δ-amyrone extracts as main component as stringy stonecrop dichloromethane extract.
It is furthermore preferred that the stringy stonecrop dichloromethane extract is prepared as follows：Stringy stonecrop drying herb is cleaned, and is used
The ethyl alcohol that volume fraction is 95% extracts, and is condensed into medicinal extract, and medicinal extract passes through silicagel column, is first eluted to petroleum ether colourless, then uses
Dichloromethane eluent collects dichloromethane eluant to colourless, recycles dichloromethane organic solution, and the medicinal extract after concentration is chilled
It is drying to obtain stringy stonecrop dichloromethane extract.
Preferably, ethyl alcohol adds in 6 times that volume is equivalent to medicinal material weight in extraction process.
2nd, a kind of preparation method of the stringy stonecrop dichloromethane extract of protection hepatic injury, is as follows：Stringy stonecrop
Dry herb is cleaned, and is extracted with the ethyl alcohol that volume fraction is 95%, is condensed into medicinal extract, and medicinal extract passes through silicagel column, first uses petroleum ether
It is eluted to colourless, then with dichloromethane eluent to colourless, collects dichloromethane eluant, recycle dichloromethane organic solution, it is dense
Medicinal extract after contracting is freeze-dried, obtains to protect the stringy stonecrop dichloromethane extract of hepatic injury.
Preferably, ethyl alcohol adds in 6 times that volume is equivalent to medicinal material weight in extraction process.
Preferably, the mass fraction of δ-amyrone is more than in the stringy stonecrop dichloromethane extract of gained protection hepatic injury
50%.
Stringy stonecrop drying herb is cleaned, is carried with the ethyl alcohol that volume fraction is 95% by the 3rd, preparation method of δ-amyrone
It takes, is condensed into medicinal extract, medicinal extract passes through silicagel column, is first eluted to petroleum ether colourless, then is collected with dichloromethane eluent to colourless
Dichloromethane eluant, eluent have Precipitation, and filtering discards filtrate, and precipitation is active ingredient.Preferably, extraction process
Middle ethyl alcohol adds in 6 times that volume is equivalent to medicinal material weight.
The invention has the advantages that：
1. the low polarity dichloromethane extract that the present invention is prepared using stringy stonecrop herb as primary raw material, is demonstrate,proved through pharmacological evaluation
The bright extract has preferable protective effect to hepatic injury, and toxic side effect is smaller, the preparation available for liver protection class drug；
2. it is found that in the extract that main component δ-amyrone have liver-protecting activity, the system through δ-amyrone of the present invention
Preparation Method can effectively remove impurity component, and the short time obtains a large amount of active ingredient, and the preparation method is simple and practicable, cost
It is low, it is efficient.
Description of the drawings
In order to make the purpose of the present invention, technical solution and advantageous effect clearer, the present invention provides drawings described below and carries out
Explanation：
Fig. 1 shows stringy stonecrop dichloromethane extract to Liver Function serum in ANIT induced rat liver injury models
Influence (a of biochemical indicator：ALT；b：AST；c：ALP；d：GGT/γ-GT；e：DBiL；f：TBiL；g：ALB；h： TP；In figure
Control is blank group, and Model is model group, and BDA is positive drug bifendate group, and Low is dichloromethane extract low dosage
Group 100mg/kg, Medium are dichloromethane extract middle dose group 200mg/kg, and High is dichloromethane extract high dose
Group 400mg/kg.Compared with blank group：*p<0.05,**p<0.01；Compared with model group：#p<0.05, ##p<0.01).
Fig. 2 shows the variation of liver tissues of rats pathological section after the treatment of stringy stonecrop dichloromethane extract：In figure
Control is blank group, and Model is model group, and BDA is positive drug bifendate group, and Low is dichloromethane extract low dosage
Group 100 mg/kg, Medium are dichloromethane extract middle dose group 200mg/kg, and High is dichloromethane extract high dose
400 mg/kg of group.
Fig. 3 is shown after the treatment of stringy stonecrop dichloromethane extract to the influence (a of inflammatory factor in rat blood serum：Tumour
Necrosis factor-alpha (TNF-α), b：Interferon-γ (IFN-γ)；c：Interleukin-4 (IL-4)；Control is blank group in figure,
Model is model group, and BDA is positive drug bifendate group, and Low is dichloromethane extract low dose group 100mg/kg,
Medium is dichloromethane extract middle dose group 200mg/kg, and High is dichloromethane extract high dose group 400mg/kg.
Compared with blank group：*p<0.05,**p<0.01；Compared with model group：#p<0.05,##p<0.01).
Fig. 4 shows influence to oxidative stress index in liver tissues of rats after the treatment of stringy stonecrop dichloromethane extract
(a：Active oxygen ROS, b：Superoxide dismutase SOD；c：Glutathione peroxidase GSH-PX；Control is blank in figure
Group, Model are model group, and BDA is positive drug bifendate group, and Low is dichloromethane extract low dose group 100mg/kg,
Medium is dichloromethane extract middle dose group 200mg/kg, and High is dichloromethane extract high dose group 400mg/kg.
Compared with blank group：*p<0.05,**p<0.01；Compared with model group：#p<0.05,##p<0.01.
Fig. 5 shows that main compound δ-amyrone in stringy stonecrop dichloromethane extract induce D-GalN
The protective effect of QSG7701 normal liver cells：(a：Compound δ-amyrone structures；b：Survival rate；c：ALT；d：AST；In figure
Control is blank group, and Model is model group, and BDA is 15 μM of positive drug bifendate group, and Low is δ-amyrone low dosages
5 μM of group, Medium are 10 μM of δ-amyrone middle dose groups, and High is 20 μM of δ-amyrone high dose groups.With blank group ratio
Compared with：*p<0.05,**p<0.01；Compared with model group：#p<0.05,##p<0.01).
Specific embodiment
Specific embodiment provided by the invention is described in detail below in conjunction with attached drawing.
The preparation of embodiment 1, stringy stonecrop dichloromethane extract
Stringy stonecrop drying herb is cleaned, and is used after being impregnated one day with the ethyl alcohol that volume fraction is 95% and is percolated extraction 3 times, and 3
The liquid of secondary extraction merges, and ethyl alcohol adds in that volume is equivalent to medicinal material weight in extraction process 6 times are concentrated under reduced pressure into medicinal extract, soak
Cream passes through silicagel column, is first eluted to petroleum ether colourless, then with dichloromethane eluent to colourless, collects dichloromethane eluant,
Dichloromethane organic solution is recovered under reduced pressure, the medicinal extract after concentration is freeze-dried up to stringy stonecrop dichloromethane extract.
The preparation of embodiment 2, compound δ-amyrone
Stringy stonecrop drying herb is cleaned, and is used after being impregnated one day with the ethyl alcohol that volume fraction is 95% and is percolated extraction 3 times, and 3
The liquid of secondary extraction merges, and ethyl alcohol adds in that volume is equivalent to medicinal material weight in extraction process 6 times are concentrated under reduced pressure into medicinal extract, soak
Cream passes through silicagel column, is first eluted to petroleum ether colourless, then with dichloromethane eluent to colourless, collects dichloromethane eluant,
Eluent has Precipitation, and filtering discards filtrate, and precipitation is active ingredient.
δ-Amyrone：White powder；13C NMR(100MHz,CDCl3)δ39.3(C-1),34.1(C-2),218.1(C-
3), 47.2(C-4),54.8(C-5),19.8(C-6),26.5(C-7),40.9(C-8),50.0(C-9),36.9(C-10),
22.2(C-11),26.5 (C-12),134.0(C-13),44.7(C-14),25.0(C-15),36.5(C-16),34.5(C-
17),133.6(C-18),39.6(C-19), 33.3(C-20),35.4(C-21),38.7(C-22),21.0(C-23),26.9
(C-24),16.2(C-25),17.6(C-26),21.2 (C-27),24.0(C-28),23.7(C-29),32.3(C-30)；1H
NMR(400MHz,CDCl3)δ1.17(3H,s),1.09(3H, s),1.02(3H,s),1.01(3H,s),0.94(6H,s),
0.88(3H,s),0.70(3H,s),2.24(d,13.8Hz,1H,H-19), 2.69(m,1H,H-2),2.46-2.48
(overlap, 2H, H-2, H-12) identifies that the compound is δ-amyrone by more than spectroscopic data.
The content of δ-amyrone in stringy stonecrop dichloromethane extract is measured using HPLC；Using δ-amyrone as standard
Product measure δ-amyrone contents more than 50%.
The liver protection drug efficacy study of embodiment 3, stringy stonecrop dichloromethane extract
1. animal packet, modeling, medication
After SD rats 60, laboratory adaptability is taken to feed 3 days, it is divided into 6 groups by weight：Blank group, model group ANIT
(70mg/kg), positive drug bifendate group (150mg/kg), low dosage administration group 100mg/kg, middle dosage administration group 200mg/
Kg, high dose administration group 400mg/kg after adaptability is fed 3 days, started administration (note in the 4th day：For the first time be administered before fasting not
Prohibit water for 24 hours), the daily gavage of each group animal 2 times (12h is primary), continuous gavage 5 days or one week, after last dose 1h, except sky
White group is outer, and every group of rats by intraperitoneal injection ANIT (70mg/kg) prepares Liver Damage in Rats model, and after 12h is administered in modeling, rat carries out
Eye socket takes blood, detaches serum, carries out the measure of Biochemical Indices In Serum and the detection of serum inflammatory factors of senile, put to death after eye socket takes blood
Rat takes liver tissues of rats, carries out liver histopathology inspection and the detection of hepatic tissue oxidative stress index.
2. the measure of Biochemical Indices In Serum
A part of rat blood is placed in EDTA-Na2 anticoagulant tube mixings, centrifuges (3000r/min, 10min), detaches serum,
Automatic clinical chemistry analyzer measures serum alt, AST, ALP, the value of GGT/ γ-GT, DBiL, TBiL, ALB, TP.
Experimental result is shown in Fig. 1, and compared with blank group, model group ALT, AST, ALP, GGT/ γ-GT, DBiL, TBiL is apparent
Raising, ALB and TP are substantially reduced, the statistically significant (P of difference<0.01), illustrate ANIT induced rat liver injury model modelings
Success.Compared with model group, stringy stonecrop dichloromethane extract middle dosage (200mg/kg), high dose (400mg/kg) administration
The ALT of hepatic injury rat, AST, ALP can be reduced afterwards, and GGT/ γ-GT, DBiL, TBiL are horizontal, can also increase ALB and TP
Content, and have certain dose-effect relationship.The result shows that stringy stonecrop dichloromethane extract has significantly ANIT induced rat hepatic injuries
Protective effect.
3. hepatic tissue pathology cut sections for microscopic examination
A part of liver tissues of rats is put in 10% formalin solution of volume fraction and is fixed, through dehydration, transparent waxdip, packet
It buries, is sliced, spread out piece, observation hepatic tissue pathology variation after h and E dyeing.
Experimental result is shown in Fig. 2, hepatic tissue pathology slice the result shows that, the lobuli hepatis structure of blank group is clear, liver cell row
Row are neat, the changes such as no swelling, atrophy, also there are no the pathological changes such as apparent denaturation, necrosis and inflammation；The liver of model group is thin
Cellular damage is apparent, and liver rope is disorganized, and degeneration of liver cells necrosis is apparent, prompts modeling success；Stringy stonecrop dichloromethane extract
The pathological changes such as administration group degeneration of liver cells, necrosis, inflammatory reaction have different degrees of improvement, and wherein high dose group liver cell becomes
Property, necrosis, inflammatory reaction are substantially reduced, liver cell queueing discipline.
4. the detection of serum inflammatory factors of senile
A part of rat blood is placed in EDTA-Na2 anticoagulant tube mixings, centrifuges (3000r/min, 10min), detaches serum,
Using TNF-α in ELISA method detection serum, the value of IFN-γ and IL-4.
Experimental result is shown in Fig. 3, model group is compared with blank group, and TNF-α and IFN-γ content significantly increase in rat blood serum,
IL-4 levels significantly reduce, hints model success.Compared with model group, stringy stonecrop dichloromethane extract administration group can drop
It is horizontal to improve anti-inflammatory factors IL-4 for proinflammatory factor TNF-α and IFN-γ content in low rat blood serum.The result shows that stringy stonecrop dichloro
Methane extract can mitigate inflammatory reaction caused by ANIT induced rat hepatic injuries.
5. the detection of hepatic tissue oxidative stress index
A part of liver tissues of rats is placed in cold saline cleaning and is placed on EP pipes, and -80 DEG C are stored in after putting into liquid nitrogen frozen,
Sample is taken out during measure, shreds hepatic tissue in operation on ice, volume ratio by weight is subject to the liver cell that physiological saline is made 10%
Homogenate, 3000r/min, 4 DEG C of low-temperature centrifugation 5min take supernatant, measure SOD, the value of ROS, GSH-Px.
Experimental result is shown in Fig. 4, model group is compared with blank group, and SOD and GSH-Px activity is notable in liver tissues of rats homogenate
It reduces, ROS contents significantly increase, hints model success.Compared with model group, stringy stonecrop dichloromethane extract administration group can be with
Antioxygen enzyme SOD and GSH-Px activity in liver tissue homogenate are improved, reduces ROS contents.The result shows that stringy stonecrop dichloromethane extracts
Object can mitigate response to oxidative stress caused by ANIT induced rat hepatic injuries.
The protective effect of QSG7701 normal liver cells that embodiment 4, compound δ-amyrone induce D-GalN
Normal liver cell's strain QSG7701 is placed in 96 orifice plates, and 3 × 104Cells/well is placed in 37 DEG C, 5%CO2Incubator
After interior 24 hours, supernatant is abandoned in suction, and replacement culture solution is simultaneously double with various dose δ-amyrone (5,10,20 μM) and positive drug biphenyl
Then ester (15 μM) sample pretreatment 12 hours adds in the D-GalN (35mM) prepared and is incubated 24 hours, collects cell training
It supports supernatant and measures ALT, AST yield, the survival rate of Simultaneous Determination liver cell.
1. the measure of hepatocyte viability
D-GalN (35mM) was incubated liver cell after 24 hours, adds in MTT (100 μ L, 0.5mg/mL) and 4 are cultivated in incubator
After hour, all liq in hole is discarded, each hole adds in 100 μ L DMSO, and concussion is measured with microplate reader under 570 nm wavelength for 10 minutes
Absorbance.With blank group absorbance value as reference, cells survival rate is 100%, other each group absorbance values and blank group
Absorbance value is made comparisons to obtain its survival rate.
The measure of 2.ALT, AST content
D-GalN (35mM) was incubated liver cell after 24 hours, collects supernatant after ten minutes through centrifugation, directly measures supernatant
Middle ALT, AST content, is as a result represented with U/L.
Experimental result is shown in Fig. 5, compared with blank group, the Human normal hepatocyte QSG7701's of D-GalN inductions deposits model group
Motility rate is decreased obviously, and ALT, AST content dramatically increase, hints model success.Compared with model group, agent in δ-amyrone
Amount (10 μM), high dose (20 μM) group can significantly improve D-GalN and induce the survival rate of QSG7701 cells and reduction liver thin
ALT, AST caused by cellular damage are horizontal.The result shows that δ-amyrone there is protection to make D-GalN induction QSG7701 liver cells
With.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, under the premise of inventive method is not departed from, can also make several improvement and supplement, these are improved and supplement also should be regarded as this
The protection domain of invention.
Claims (9)
1. δ-amyrenone or the answering in the drug for preparing protection hepatic injury with δ-amyrenone extract as main component
With.
2. application according to claim 1, it is characterised in that：It is described with δ-amyrenone extract δ as main component-
The mass fraction of amyrenone is more than 50%.
3. application according to claim 1, it is characterised in that：It is described using δ-amyrenone extract as main component as
Stringy stonecrop dichloromethane extract.
4. application according to claim 2, it is characterised in that：The stringy stonecrop dichloromethane extract is made as follows
It is standby：Stringy stonecrop drying herb is cleaned, and is extracted with the ethyl alcohol that volume fraction is 95%, is condensed into medicinal extract, and medicinal extract passes through silicagel column, first
It is eluted to petroleum ether colourless, then with dichloromethane eluent to colourless, collects dichloromethane eluant, recycling dichloromethane is organic
Solution, the medicinal extract after concentration are freeze-dried up to stringy stonecrop dichloromethane extract.
5. application according to claim 4, it is characterised in that：Ethyl alcohol adds in volume and is equivalent to medicinal material weight in extraction process
6 times.
6. a kind of preparation method of the stringy stonecrop dichloromethane extract of protection hepatic injury, which is characterized in that be as follows：
Stringy stonecrop drying herb is cleaned, and is extracted with the ethyl alcohol that volume fraction is 95%, is condensed into medicinal extract, and medicinal extract passes through silicagel column, first uses
Petroleum ether is eluted to colourless, then with dichloromethane eluent to colourless, collects dichloromethane eluant, recycling dichloromethane is organic molten
Liquid, the medicinal extract after concentration is freeze-dried, obtains to protect the stringy stonecrop dichloromethane extract of hepatic injury.
7. a kind of preparation method of the stringy stonecrop dichloromethane extract of protection hepatic injury according to claim 6, feature
It is, ethyl alcohol adds in volume and is equivalent to 6 times of medicinal material weight in extraction process.
8. a kind of preparation method of the stringy stonecrop dichloromethane extract of protection hepatic injury according to claim 5, feature
It is：The mass fraction of δ-amyrenone is more than 50% in the stringy stonecrop dichloromethane extract of gained protection hepatic injury.
9. the preparation method of δ-amyrenone, it is characterised in that：Stringy stonecrop drying herb is cleaned, is 95% with volume fraction
Ethyl alcohol extracts, and is condensed into medicinal extract, and medicinal extract passes through silicagel column, be first eluted to petroleum ether it is colourless, then with dichloromethane eluent to nothing
Color collects dichloromethane eluant, and eluent has Precipitation, and filtering discards filtrate, and precipitation is active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810096090.7A CN108125964A (en) | 2018-01-31 | 2018-01-31 | δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810096090.7A CN108125964A (en) | 2018-01-31 | 2018-01-31 | δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108125964A true CN108125964A (en) | 2018-06-08 |
Family
ID=62430358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810096090.7A Pending CN108125964A (en) | 2018-01-31 | 2018-01-31 | δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108125964A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697822A (en) * | 2012-06-04 | 2012-10-03 | 江苏大学 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
-
2018
- 2018-01-31 CN CN201810096090.7A patent/CN108125964A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697822A (en) * | 2012-06-04 | 2012-10-03 | 江苏大学 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
| CN102697822B (en) * | 2012-06-04 | 2014-04-09 | 江苏大学 | Application of sargentg loryvine stem active fraction to preparation of anti-inflammatory-immune and anti-ageing medicaments |
Non-Patent Citations (2)
| Title |
|---|
| 李慧娟等: "垂盆草的化学成分分离鉴定", <<中国实验方剂学杂质>> * |
| 魏太明: "垂盆草化学成分及其质量研究", <<北京中医药大学博士研究生学位论文>> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
| CN102274244B (en) | Cassia bark polyphenol extract and preparation method and application thereof | |
| Hernández-Galicia et al. | Monoglycerides and fatty acids from Ibervillea sonorae root: isolation and hypoglycemic activity | |
| Vaidya | Review on gymnema: an herbal medicine for diabetes management | |
| CN104387438B (en) | New triterpene saponin componds Herba Celosiae argenteae glycosides L in Semen Celosiae and its medical application | |
| CN109232491A (en) | The Preparation method and use of benzofuran compounds in a kind of Herba Serissae | |
| CN102151281B (en) | Flavonoid compound for preventing and treating diabetes and medicament application thereof | |
| CN101570557B (en) | Compound in cyclocarya paliurus and application thereof in medicament field | |
| EP1559703A1 (en) | A natural compound useful for treating diabetes, its preparation and use | |
| CN106220701A (en) | triterpene compound and preparation method and application thereof | |
| CN101301300A (en) | Medicament composition | |
| CN104341478B (en) | Triterpene saponin componds feather cockscomb glycosides K and its medical application in the seed of feather cockscomb | |
| CN108125964A (en) | δ-amyrenone or the application with δ-amyrenone extract as main component in the drug for preparing protection hepatic injury | |
| CN106496245A (en) | The pharmaceutical composition of lisinopril and its application in biological medicine | |
| CN105147711B (en) | A kind of preparation of Fructus Forsythiae active site and its application in prevention and treatment Parkinson's disease | |
| Tatipamula et al. | Isolation and Characterization of metabolites from Clathria procera Ridley extract and Evaluation of its antidiabetic effects in Streptozotocin-induced diabetic rats | |
| CN113666804A (en) | Fermented gastrodia elata extract with anti-depression activity and preparation and application thereof | |
| CN106800579A (en) | A kind of method of separation and Extraction Rabdosia infedus glycosides A from common rabdosia leaf and application | |
| Andrade-Cetto et al. | Hypoglycemic effect of Hamelia patens Jacq., aerial part in STZ-NA-induced diabetic rats | |
| CN101856357B (en) | Application of rotundic acid in preparing medicines for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN102361644A (en) | Anti dengue activity of cissampelos pareira extracts | |
| CN115869356B (en) | Preparation of barb active site for anti-trichina medicine | |
| CN114736182B (en) | Compound for resisting myocardial ischemia reperfusion injury, dai medicine composition and application thereof | |
| CN101914128B (en) | Preparation method of buddlejasaponins IV, product thereof and use thereof | |
| Sarkar et al. | Study of hypoglycemic activity of aqueous extract of Leucas indica Linn. aerial parts on streptozotocin induced diabetic rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180608 |
|
| RJ01 | Rejection of invention patent application after publication |